Mortality in Sjogren's syndrome

Voulgarelis, M; Tzioufas, AG; Moutsopoulos, HM

dc.contributor.author	Voulgarelis, M	en
dc.contributor.author	Tzioufas, AG	en
dc.contributor.author	Moutsopoulos, HM	en
dc.date.accessioned	2014-03-01T01:57:28Z
dc.date.available	2014-03-01T01:57:28Z
dc.date.issued	2008	en
dc.identifier.issn	0392-856X	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28427
dc.subject	Sjogren's syndrome.	en
dc.subject	mortality	en
dc.subject	lymphoma	en
dc.subject	cryoglobulins.	en
dc.subject	risk factors	en
dc.subject.classification	Rheumatology	en
dc.subject.other	LYMPHOID-TISSUE LYMPHOMA	en
dc.subject.other	NON-HODGKINS-LYMPHOMA	en
dc.subject.other	HEPATITIS-C VIRUS	en
dc.subject.other	B-CELL LYMPHOMA	en
dc.subject.other	MALIGNANT-LYMPHOMA	en
dc.subject.other	RHEUMATIC DISEASES	en
dc.subject.other	PROGNOSTIC-FACTORS	en
dc.subject.other	LIGHT-CHAINS	en
dc.subject.other	RISK	en
dc.subject.other	CLASSIFICATION	en
dc.title	Mortality in Sjogren's syndrome	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2008	en
heal.abstract	Sjogren's syndrome (SS) is a chronic autoimmune diseae that involves primarily the exocrine glands and results in their functional impairment. The disease may occur alone (primary SS.pSS) or in association with other autoimmune diseases, such as rheumatoid arthritis (secondary SS, sSS). Although the clinical manifestations of pSS patients are mainly those of an autoimmune exocrinopathy. 40% to 50% of patients develop extraglandular disease, which may be manifested either by epithelial lymphocytic invasion of lung, lier, or kidney (resulting in interstitial nephritis) or by skin vasculitis, peripheral neuropathy, glomerulone-nephritis and low C4 levels, conditions which represent an immune-complex mediated disease. Patients belonging to the latter category, inferring a high risk for development of non-Hodgkin's lymphoma, by default have a worse prognosis with higher mortality rates. In this review, the role of several factors involved in mortality of pSS, as well as markers predictive for lymphoma development are discussed.	en
heal.publisher	CLINICAL & EXPER RHEUMATOLOGY	en
heal.journalName	CLINICAL AND EXPERIMENTAL RHEUMATOLOGY	en
dc.identifier.isi	ISI:000260467300008	en
dc.identifier.volume	26	en
dc.identifier.issue	5	en
dc.identifier.spage	S66	en
dc.identifier.epage	S71	en